PHARMA
APOLLOHOSP is forming triangle patternNSE:APOLLOHOSP Large cap Health care stock is forming triangle pattern with 4 months support line and 9 months resistance line with 4 rejections.
Previous support line was broken at 2022-04-29 and fallen 25%, hence this time enter only on strong breakout and follow strict SL.
Shorting can be attempted with triangle's support is broken strongly, and SL need to be followed strictly.
Key note : Always follow proper risk management to avoid losing capital from false breakouts as this is common.
Caution : This is a knowledge sharing analysis, not a call.
Profits are not made from following ideas, but by following Risk Management .
NIFTY PHARMA, REACHED ITS BOTTOM!!the dark black trend lines drawn are the actual positions where the nifty pharma should carry on, i have drawn a support line from the corona crash till date, which shows markets have bottomed. please do read the text mentioned in the graph, to understand my full analysis..
SOLARA ACTIVE PHARMA, AT A HUGE DISCOUNT!!i have marked the time of corona crash(2019), with a circle, this stock had not broken its support during a crash too, that means its a stable stock.
it has a good fundamentals, due to heavy corrections from past year, this stock had corrected a lot.
i have drawn a 5 wave pattern, and this stock will now stock its bull rally, as markets for large caps have corrected, and now its time for mid and small caps to get its bull run. (link provided below).
the stock has corrected till its IPO PRICE(when it touched its bottom).
this stock has a good future, invest for long term
Nifty Pharma- Support and Resistance ZoneNifty Pharma- Support and Resistance Zone
Consider buying Nifty Pharma stocks above resistance zone ( We can wait till 4 hours candle close above resistance)
Consider selling Nifty Pharma stocks below support zone ( We can wait till 4 hours candle close below support)
Mid term swing opportunity in CTI BioPharma (CTIC)Stock had decent drop right after earnings to the lowest channel support line.
Stock is heavily short : 20% of float is short
80% Institutional investors.
nice swing opportunity for a re-bounce to the upper "resistance" channel line.
NASDAQ:CTIC
LXRX PENNY BIOTECH SHORT SETUPNASDAQ:LXRX
LXRX has gained over 100% in the past month
However it appears to be forming a double top
in a potential short trade setup on the two hour chart.
The K/D crossover on the hot RSI oscillator provides
confirmation.
Short Sale Volume is rising in the past two days.
Findamentals - LXRX has a new medication for heart failure
a common medical problem with a massive market
It recently launched a public offering to raise capital
to fund general operations and in doing so
diluted the share holders. The good news is
it is unlikely to do another in the near term.
An entry would be at the current price with a stop loss
above the highest volume bar on the profile.
The first target is the POC of the volume profile
about a 15% price drop . The second target is
the pivot low on August 1st for another 15% drop.
Taking of 1/2 at each target yields an expected
23% return over a period of about 5 trading days
since drops are faster than rises.
The call options of mid September have low volumes
so I will not consider them.
ASND ( NASDAQ BIOTECH) rises on earnings and FDA submissionNASDAQ:ASND
as can be seen on the hourly chart ASND is in an uptrend
recent earnings were a good beat,
RSI is quite high and it is at one than one STD above
the multi-session VWAP.
ASND is on watch for a pullback to find an entry
as it has high upside.
CLVS signs of Life? Break outAfter following this since hit flat lined at .81 cent I saw clear cut signs of accumulation and break out. Right at the end of the option chain cycle. Which ended today. The fact that it jumped to above a $1 on this day shows to me that its serious about bouncing off the bottom. Otherwise it could have just stayed below $1 until after today. It jumping above a dollar today means someone lost money or that they dragged it so far down that even if it came up it didnt matter..... Now we have a full month in this option call to run. does it go parabolic? or does it re-accumulate from here to inch its way back up?
i marked two key areas in blue for when obvious change tot he price action can happen.
by iCantw84it
06.17.22
7/17/22 LLYEli Lilly and Company ( NYSE:LLY )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $315.073B
Current Price: $331.60
Breakout price: $334.70
Buy Zone (Top/Bottom Range): $314.00-$292.90
Price Target: $364.20-$367.50 (2nd)
Estimated Duration to Target: 112-120d (2nd)
Contract of Interest: $LLY 10/21/22 350c
Trade price as of publish date: $13.50/contract
Novavax - Wassup?Novavax NVAX is actually lining up pretty well... from about 240, it tanked to 40, and on Friday, it gained 11% to close the week at 57.15.
This caught my attention as it cleanly broke out of trendlines, breaking out also from a bearish divergence, on BOTH the weekly and daily chart.
IMHO, it appears to be in technical and fractal alignment.
Weekly chart bounced off a major support two weeks ago, and the last week continued the previous week's bullish end. On the daily chart, Friday's close was the highest daily close in about 5 weeks. with a strong candle closing draws obvious bullish attention.
Target 80, then 125.
Support at 53 and 50.
Moderna Progress on all VaccinesThe statistics are between $184 - $219(1 Year)
Its Financial Health is very strong.
Why not wait till Moderna makes greater progress and finds It
Resistance Again at $450
Moderna has many projects running.
So if we see progress in some of the projects in the next Years,
we will see a great price rise.
I believe it won't be difficult to reach its older resistance again, around $450.
Disclaimer:
Just my Idea! Find your Trading Ideas and learn and study more!
6/20/22 MRKMerck & Company, Inc. ( NYSE:MRK )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $213.987B
Current Price: $84.62
Breakout price: $91.40
Buy Zone (Top/Bottom Range): $83.60-$79.90
Price Target: $103.20-$105.80
Estimated Duration to Target: 672-696d
Contract of Interest: $MRK 1/19/24 85c
Trade price as of publish date: $10.17/contract
Sanofi - Pharming for profits?Sanofi
Short Term
We look to Buy at 95.00 (stop at 91.90)
The medium term bias remains bullish. Levels close to the 50% pullback level of 93.25 found buyers. Previous support located at 93.08. Further upside is expected and we look to set longs in early trade.
Our profit targets will be 104.35 and 110.00
Resistance: 95.16 / 98.22 / 104.35
Support: 93.25 / 93.08 / 92.78
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
SUNPHARMA (Trade the Trend) - BullishSUNPHARMA - Sun Pharmaceutical Industries Ltd. NSE:SUNPHARMA
After Q4 Results we saw a good sell-off in Sunpharma, yet the price hardly moved much
Shanghvi stated "Our India business continues to grow faster than the market, leading to an increase in market share. We continue to focus on expanding our global specialty business, growing all our businesses, and improving operational efficiencies," stated.
The company said its board has proposed a final dividend of Rs 3 per share for FY22.
One can plan a long position between 835 to 840 with a strict SL of Rs 825 for short term trading (01 to 02 weeks) and SL if the price moves below 825 (Daily candle close) for long term swing trading (greater than 2 weeks)
Short Term targets are up to - 886
Long Term Target is up to - 929
Risk Reward for this trade is very good
#Learn&earn #Wealth #Editor's Choice #trending #Weathmagnet candlestick analysis, candlestick stock pattern
Do Support by Liking and Commenting on our Post as it motivates us to post more such ideas
The chart is for study purposes only!!
Kindly consult your Financial Advisor before investing any money
The big "Legalize It"Fundamentals:
+ Weed
+ Established pharma and re-creational contacts.
+ Key moment for the "Legalize it" movement
Opinion:
Cron and Aurora canabis are the main names in the publicly traded cannabis's industry. As governments attempt to fight inflation while walking the recession line, it becomes a "Win-Win" for legalization and governments. A number of countries still have restrictions on cannabis but whilst fighting inflation and hunting for taxable income, the next 24 months may prove to be the most legaly accommodating towards this new industry. This week Thailand made the move. The idea is that they wont be the last! #Long
Notes on how I personally use my charts/NFA:
Each level L1-L3 and TP1-TP3 has a deployment percentage. The idea is to flag these levels so I can buy 11% at L1 , 28% at L2 and if L3 deploy 61% of assigned dry powder. The same in reverse goes for TP. TP1: 61%, TP2:28% and TP3:11%. If chart pivots between TP's, in-between or in Between Sell levels these percentages are still respected. I like to use the trading range to accumulate by using this tactic.
Just my personal way of using this. This is not intended or made to constitute any financial advice.
This is not intended or made to constitute any financial advice.
FED Macro Situation Consideration:
All TP's are drawn within the context of a return to FED neutral policy. I do not expect these levels to be reached before tightening is over.
NOT INVESTMENT ADVICE
I am not a financial advisor.
The Content in this TradingView Idea is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained within this idea constitutes a solicitation, recommendation, endorsement, or offer to buy or sell any securities or other financial instruments in this or in in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction.
All Content on this idea post is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in the idea/post constitutes professional and/or financial advice, nor does any information on the idea/post constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. You alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other Content on the idea/post before making any decisions based on such information.
SIGA trading at a ridiculous premium - time to be bearishHype and sentiment regarding a monkeypox outbreak has been the only driver in SIGAs price, apart from minor PR.
Volume will slowly wither away, and investors will begin to take profits. It will not remain at this price range for much longer.
Looks to be an easy short/put. Will be opening 10$ Puts with a June 17th expiry.